LithaBone TCP 300 enables patient-specific implants with defined pore geometries. The material is resorbed by the body and replaced by new bone.
Cytotoxicity
not cytotoxic according to ISO 10993-5
Irritation and skin sensitivity
not irritating to skin according to ISO 10993-10
LithaBone TCP 300 is a slurry with a base of the ceramic material beta-tricalcium phosphate (β-TCP). Tricalcalcium phosphate (TCP) has established itself as a bone graft substitute in regenerative medicine due to excellent biocompatibility, bioresorbability and osteoconductivity.
Thanks to these advantageous properties, it is possible to manufacture patient-specific, bioresorbable implants with defined pore structures and geometries. These implants are absorbed by the body and replaced by the patient's own bone tissue, eliminating the need for a second surgery to remove the implant after the healing process.
FIELDS OF APPLICATION
